Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Inhibikase Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18
   10-K10-K10-K10-KS-1/A
Revenues  0.13.10.71.14.0
            Revenue growth  -96.0%343.9%-37.8%-72.2% 
Cost of goods sold  0.00.03.52.63.6
Gross profit  0.13.1-2.8-1.40.4
            Gross margin  100.0%100.0%-403.5%-127.4%9.7%
Selling, general and administrative  6.26.5 4.32.5
Research and development  12.011.4   
Other operating expenses    -1.4  
EBIT   [+]-18.1-14.8-1.4-5.7-2.1
            EBIT margin  -14686.2%-476.2%-201.1%-507.5%-52.5%
Interest expense, net   [+]-0.10.0 0.00.0
Other income (expense), net    -1.4  
Pre-tax income  -18.1-14.8-2.8-5.7-2.2
Income taxes  0.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%
Net income  -18.1-14.8-2.8-5.7-2.2
            Net margin  -14625.9%-476.9%-407.7%-509.7%-53.3%
   
Basic EPS   [+]($0.72)($0.81)($0.35)  
Diluted EPS   [+]($0.72)($0.81)($0.35)  
   
Shares outstanding (basic)   [+]25.218.28.2  
Shares outstanding (diluted)   [+]25.218.28.2  
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy